Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Nephrol. doi: /nrneph

Published byRudīte Lūsis Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Nephrol. doi: /nrneph"— Presentation transcript:

1 Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.91
Figure 5 Cross sections of kidneys from a rat model of polycystic kidney disease (cy/+ Han:SPRD) Figure 5 | Cross sections of kidneys from a rat model of polycystic kidney disease (cy/+ Han:SPRD). a,c | Control animals. b,d | Animals treated with the epidermal growth factor receptor (EGFR) inhibitor EKI-785. Administration of EKI-785 reduced the severity of cystic disease as reflected by a decrease in kidney size, reduced cyst development and less fibrosis. Reproduced with permission from © 2003 International Society of Nephrology. Published by Elsevier Inc. Torres, V. E. et al. Kidney Int. 64, 1573–1579 (2003)102. Reproduced with permission from © 2003 International Society of Nephrology. Published by Elsevier Inc. Torres, V. E. et al. Kidney Int. 64, 1573–1579 (2003)102. Harskamp, L. R. et al. (2016) The epidermal growth factor receptor pathway in chronic kidney diseases Nat. Rev. Nephrol. doi: /nrneph

Download ppt "Nat. Rev. Nephrol. doi: /nrneph"

Similar presentations

Volume 66, Issue 5, Pages (November 2004)

Volume 66, Issue 5, Pages (November 2004)
Volume 66, Issue 5, Pages (November 2004)

Volume 66, Issue 5, Pages (November 2004)
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.
Figure 4 Interplay between acute kidney injury (AKI),

Figure 4 Interplay between acute kidney injury (AKI),
Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.

Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.
Figure 6 Effects of adiponectin on podocyte function

Figure 6 Effects of adiponectin on podocyte function
Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.
Figure 2 Pathology of scleroderma renal crisis

Figure 2 Pathology of scleroderma renal crisis
Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.
Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Expression of coagulation protease receptors in renal cells
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 1 Mechanisms of kidney injury in the setting of obesity
Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Physiological changes in the renal system in pregnancy
Figure 2 Proinflammatory mechanisms in CKD

Figure 2 Proinflammatory mechanisms in CKD
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 4 BMI and mortality in patients with heart failure

Figure 4 BMI and mortality in patients with heart failure
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.
Figure 7 The efficacy of phosphate-binder therapy

Figure 7 The efficacy of phosphate-binder therapy

Similar presentations

Ads by Google